Discovery
|
Julia Schueler, DVM
What's Hot in 2024: Digital Twins
Virtual representations of patients, tumors and biological processes will help to transform oncology drug discovery
The concept of “digital twins” in drug discovery represents a cutting-edge approach that leverages computational models to simulate and analyze biological systems at an individualized level. This technology enables researchers to create virtual representations of patients, tumors, and biological processes, allowing for more accurate predictions and biomarker development. By creating digital twins for different tumor types, researchers can design preclinical studies that more accurately represent the characteristics of individual cancers. Using well-characterized patient-derived xenograft (PDX) biobanks increases the translational value of the digital twins. Through the simulation of drug responses in digital twins, scientists can identify potential biomarkers associated with positive or negative treatment outcomes.
In short, digital twins offer a transformative approach to drug discovery by providing a predictive framework for tumor types, biomarkers, and drug candidates. The ability to simulate genetic variations, disease progression, and drug responses at an individual level enhances the efficiency and effectiveness of the drug discovery process, particularly in the field of oncology. Expect to see more examples of this technology in the drug discovery space next year and beyond.
—Julia Schueler, Therapeutic Area Lead, Oncology, Charles River
Oncology & Immuno-Oncology Studies
To reach the clinic in record time, it’s vital to test your oncology therapies in systems that reflect the disease seen in humans. We are here to help with a range of translational oncology studies, including in vitro assays and in vivo models, that mirror human cancers.